KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect of cancer treatments like paclitaxel and oxaliplatin, often forcing patients to reduce or stop life-saving therapy. Current treatments for CIPN are limited in efficacy and frequently carry significant side effects, including sedation and abuse potential. This study investigates whether KLS-13019, a novel structural analogue of cannabidiol (CBD) and a selective GPR55 receptor antagonist, can prevent or reverse CIPN in rat models.

The researchers utilized Sprague-Dawley rats sensitized to chemotherapy using paclitaxel or oxaliplatin. They assessed mechanical and cold allodynia (pain response to non-painful stimuli) across three paradigms: acute reversal (single dose), chronic reversal (repeated doses), and prevention (co-administration with chemotherapy). The study compared KLS-13019 against standard clinical drugs (morphine, gabapentin, duloxetine, indomethacin) and other GPR55-targeted molecules, while also evaluating sex differences and potential sedative effects via drug discrimination tasks.

KLS-13019 demonstrated robust, dose-dependent efficacy in both preventing and reversing CIPN-related allodynia. Unlike morphine, which showed sedative effects and tolerance, KLS-13019 provided durable relief without inducing sedation or tachyphylaxis (diminished response over time). Notably, when administered proximally to chemotherapy, KLS-13019 prevented the development of the allodynic phenotype entirely. The drug was equally effective in male and female rats and showed promising oral bioavailability, suggesting it could be a viable therapeutic candidate for clinical use.

This research identifies GPR55 as a promising target for managing CIPN, a condition with a significant unmet medical need. KLS-13019 offers a potential advantage over existing therapies by providing superior efficacy without the common side effects associated with current pain management options. By preventing the transition from acute to chronic pain, this compound could significantly improve the quality of life for cancer patients and potentially allow them to complete their full chemotherapy regimens.